Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients

Journal of Molecular Diagnostics

Volumn 18, Issue 2, 2016, Pages 176-189

  Alikian, Mary ^a   Ellery, Peter ^a   Forbes, Martin ^a   Gerrard, Gareth ^a   Kasperaviciute, Dalia ^b   Sosinsky, Alona ^b   Mueller, Michael ^b   Whale, Alexandra S ^c   Milojkovic, Dragana ^d   Apperley, Jane ^a   Huggett, Jim F ^c   Foroni, Letizia ^a   Reid, Alistair G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LGC   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL1 PROTEIN; DNA; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL IMAGING; DNA BASED DIGITAL POLYMERASE CHAIN REACTION; FOLLOW UP; GENE IDENTIFICATION; GENE MAPPING; GENOMICS; HUMAN; HUMAN TISSUE; LEUKEMIA REMISSION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MINIMAL RESIDUAL DISEASE; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATHOLOGY; PROCEDURES;

FUSION PROTEINS, BCR-ABL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECISION MEDICINE; SENSITIVITY AND SPECIFICITY;

EID: 84960801913     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2015.09.005     Document Type: Article

References (48)

1. J.W. Vardiman Chronic myelogenous leukemia, BCR-ABL1+ Am J Clin Pathol 132 2009 250 260
2. M. Bjorkholm, L. Ohm, S. Eloranta, A. Derolf, M. Hultcrantz, J. Sjoberg, T. Andersson, M. Hoglund, J. Richter, O. Landgren, S.Y. Kristinsson, and P.W. Dickman Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008 J Clin Oncol 29 2011 2514 2520
3. M. Baccarani, M.W. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J.F. Apperley, F. Cervantes, R.E. Clark, J.E. Cortes, F. Guilhot, H. Hjorth-Hansen, T.P. Hughes, H.M. Kantarjian, D.W. Kim, R.A. Larson, J.H. Lipton, F.X. Mahon, G. Martinelli, J. Mayer, M.C. Muller, D. Niederwieser, F. Pane, J.P. Radich, P. Rousselot, G. Saglio, S. Saussele, C. Schiffer, R. Silver, B. Simonsson, J.L. Steegmann, J.M. Goldman, and R. Hehlmann European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Blood 122 2013 872 884
4. F.X. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Etienne, J. Reiffers, P. Rousselot Intergroupe Francais des Leucemies Myeloides Chroniques Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 2010 1029 1035
5. P. Rousselot, F. Huguet, D. Rea, L. Legros, J.M. Cayuela, O. Maarek, O. Blanchet, G. Marit, E. Gluckman, J. Reiffers, M. Gardembas, and F.X. Mahon Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 2007 58 60
6. P. Rousselot, A. Charbonnier, P. Cony-Makhoul, P. Agape, F.E. Nicolini, B. Varet, M. Gardembas, G. Etienne, D. Réa, L. Roy, M. Escoffre-Barbe, A. Guerci-Bresler, M. Tulliez, S. Prost, M. Spentchian, J.M. Cayuela, J. Reiffers, J.C. Chomel, A. Turhan, J. Guilhot, F. Guilhot, and F.X. Mahon Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease J Clin Oncol 32 2014 424 430
7. D.M.1. Ross, S. Branford, J.F. Seymour, A.P. Schwarer, C. Arthur, D.T. Yeung, P. Dang, J.M. Goyne, C. Slader, R.J. Filshie, A.K. Mills, J.V. Melo, D.L. White, A.P. Grigg, and T.P. Hughes Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study Blood 122 2013 515 522
8. N. Thielen, Holt B. van der, J.J. Cornelissen, G.E. Verhoef, T. Gussinklo, B.J. Biemond, S.M. Daenen, W. Deenik, Kooy R. van Marwijk, E. Petersen, W.M. Smit, P.J. Valk, G.J. Ossenkoppele, and J.J. Janssen Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON) Eur J Cancer 49 2013 3242 3246
9. J.V. Melo, and D.M. Ross Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematology Am Soc Hematol Educ Program 2011 2011 136 142
10. L. Foroni, G. Wilson, G. Gerrard, J. Mason, D. Grimwade, H.E. White, D.G. de Castro, S. Austin, A. Awan, E. Burt, T. Clench, J. Farruggia, J. Hancock, A.E. Irvine, A. Kizilors, S. Langabeer, B.J. Milner, G. Nickless, A. Schuh, A. Sproul, L. Wang, C. Wickham, and N.C. Cross Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia Br J Haematol 153 2011 179 190
11. L. Foroni, G. Gerrard, E. Nna, J.S. Khorashad, D. Stevens, B. Swale, D. Milojkovic, A. Reid, J. Goldman, and D. Marin Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia Am J Hematol 84 2009 517 522
12. P.A. Bartley, D.M. Ross, S. Latham, M.H. Martin-Harris, B. Budgen, V. Wilczek, S. Branford, T.P. Hughes, and A.A. Morley Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA Int J Lab Hematol 32 2010 e222 e228
13. M. Sobrinho-Simões, V. Wilczek, J. Score, N.C. Cross, J.F. Apperley, and J.V. Melo In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib Blood 116 2010 1329 1335
14. N.C. Cross, J.V. Melo, L. Feng, and J.M. Goldman An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders Leukemia 8 1994 186 189
15. N.C. Cross, A. Hochhaus, and M.C. Muller Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization Ann Hematol 94 Suppl 2 2015 S219 S225
16. M. Martin Cutadapt removes adapter sequences from high-throughput sequencing reads EMBnetjournal 17 2011 10 12
17. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv (1303.3997) 2013 http://arxiv.org/abs/1303.3997
18. J. Wang, C.G. Mullighan, J. Easton, S. Roberts, S.L. Heatley, J. Ma, M.C. Rusch, K. Chen, C.C. Harris, L. Ding, L. Holmfeldt, D. Payne-Turner, X. Fan, L. Wei, D. Zhao, J.C. Obenauer, C. Naeve, E.R. Mardis, R.K. Wilson, J.R. Downing, and J. Zhang CREST maps somatic structural variation in cancer genomes with base-pair resolution Nat Methods 8 2011 652 654
19. K. Chen, J.W. Wallis, M.D. McLellan, D.E. Larson, J.M. Kalicki, C.S. Pohl, S.D. McGrath, M.C. Wendl, Q. Zhang, D.P. Locke, X. Shi, R.S. Fulton, T.J. Ley, R.K. Wilson, L. Ding, and E.R. Mardis BreakDancer: an algorithm for high-resolution mapping of genomic structural variation Nat Methods 6 2009 677 681
20. A. Untergasser, I. Cutcutache, T. Koressaar, J. Ye, B.C. Faircloth, M. Remm, and S.G. Rozen Primer3-new capabilities and interfaces Nucleic Acids Res 40 2012 e115
21. S.F. Altschul, W. Gish, W. Miller, E.W. Myers, and D.J. Lipman Basic local alignment search tool J Mol Biol 215 1990 403 410
22. W.J. Kent BLAT-the BLAST-like alignment tool Genome Res 12 2002 656 664
23. P.M. Vallone, and J.M. Butler AutoDimer: a screening tool for primer-dimer and hairpin structures Biotechniques 37 2004 226 231
24. R. Sanders, J.F. Huggett, C.A. Bushell, S. Cowen, D.J. Scott, and C.A. Foy Evaluation of digital PCR for absolute DNA quantification Anal Chem 83 2011 6474 6484
25. J.F. Huggett, C.A. Foy, V. Benes, K. Emslie, J.A. Garson, R. Haynes, J. Hellemans, M. Kubista, R.D. Mueller, T. Nolan, M.W. Pfaffl, G.L. Shipley, J. Vandesompele, C.T. Wittwer, and S.A. Bustin The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments Clin Chem 59 2013 892 902
26. V.H. van der Velden, G. Cazzaniga, A. Schrauder, J. Hancock, P. Bader, E.R. Panzer-Grumayer, T. Flohr, R. Sutton, H. Cave, H.O. Madsen, J.M. Cayuela, J. Trka, C. Eckert, L. Foroni, U. Zur Stadt, K. Beldjord, T. Raff, C.E. van der Schoot, J.J. van Dongen European Study Group on MRD detection in ALL (ESG-MRD-ALL) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data Leukemia 21 2007 604 611
27. G. Gerrard, K. Mudge, R. Stewart, P. Foskett, D. Stevens, J.S. Khorashad, R. Szydlo, K. Rezvani, D. Marin, A. Reid, J. Apperley, J. Goldman, and L. Foroni Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies Am J Hematol 86 2011 313 315
28. G. Gerrard, K. Mudge, P. Foskett, D. Stevens, M. Alikian, H.E. White, N.C. Cross, J. Apperley, and L. Foroni Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization Am J Hematol 87 2012 717 720
29. J. Gabert, E. Beillard, V.H. van der Velden, W. Bi, D. Grimwade, N. Pallisgaard, G. Barbany, G. Cazzaniga, J.M. Cayuela, H. Cave, F. Pane, J.L. Aerts, D. De Micheli, X. Thirion, V. Pradel, M. Gonzalez, S. Viehmann, M. Malec, G. Saglio, and J.J. van Dongen Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program Leukemia 17 2003 2318 2357
30. G. Johnson, A.A. Nour, T. Nolan, J. Huggett, and S. Bustin Minimum information necessary for quantitative real-time PCR experiments Methods Mol Biol 1160 2014 5 17
31. A.R. Jeffs, S.M. Benjes, T.L. Smith, S.J. Sowerby, and C.M. Morris The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia Hum Mol Genet 7 1998 767 776
32. J. Score, M.J. Calasanz, O. Ottman, F. Pane, R.F. Yeh, M.A. Sobrinho-Simoes, S. Kreil, D. Ward, C. Hidalgo-Curtis, J.V. Melo, J. Wiemels, B. Nadel, N.C. Cross, and F.H. Grand Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation Leukemia 24 2010 1742 1750
33. D.M. Ross, S. Branford, J.F. Seymour, A.P. Schwarer, C. Arthur, P.A. Bartley, C. Slader, C. Field, P. Dang, R.J. Filshie, A.K. Mills, A.P. Grigg, J.V. Melo, and T.P. Hughes Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR Leukemia 24 2010 1719 1724
34. M. Sobrinho-Simoes, V. Wilczek, J. Score, N.C. Cross, J.F. Apperley, and J.V. Melo In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib Blood 116 2010 1329 1335
35. P.A. Bartley, D.M. Ross, S. Latham, M.H. Martin-Harris, B. Budgen, V. Wilczek, S. Branford, T.P. Hughes, and A.A. Morley Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA Int J Lab Hematol 32 6 Pt 1 2010 e222 e228
36. E. Mattarucchi, O. Spinelli, A. Rambaldi, F. Pasquali, F. Lo Curto, L. Campiotti, and G. Porta Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis J Mol Diagn 11 2009 482 487
37. J.G. Zhang, F. Lin, A. Chase, J.M. Goldman, and N.C. Cross Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation Blood 87 1996 2588 2593
38. P.A. Bartley, S. Latham, B. Budgen, D.M. Ross, E. Hughes, S. Branford, D. White, T.P. Hughes, and A.A. Morley A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia J Mol Diagn 17 2015 185 192
39. S. Bose, M. Deininger, J. Gora-Tybor, J.M. Goldman, and J.V. Melo The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease Blood 92 1998 3362 3367
40. Y. Shibata, A. Malhotra, and A. Dutta Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET Genome Med 2 2010 70
41. S. Akel, A. Kolialexi, A. Mavrou, C. Metaxotou, D. Loukopoulos, and X. Yataganas Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings Clin Lab Haematol 24 2002 361 367
42. S. Branford, J.F. Seymour, A. Grigg, C. Arthur, Z. Rudzki, K. Lynch, and T. Hughes BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria Clin Cancer Res 13 2007 7080 7085
43. S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J.J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J.L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J.M. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A.E. Bolton, R. Capdeville, and B.J. Druker Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
44. T. Hughes, and S. Branford Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia Blood Rev 20 2006 29 41
45. H.G. Goh, M. Lin, T. Fukushima, G. Saglio, D. Kim, S.Y. Choi, S.H. Kim, J. Lee, Y.S. Lee, S.M. Oh, and D.W. Kim Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay Leuk Lymphoma 52 2011 896 904
46. A.S. Whale, S. Cowen, C.A. Foy, and J.F. Huggett Methods for applying accurate digital PCR analysis on low copy DNA samples PLoS One 8 2013 e58177
47. A.S. Whale, J.F. Huggett, S. Cowen, V. Speirs, J. Shaw, S. Ellison, C.A. Foy, and D.J. Scott Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation Nucleic Acids Res 40 2012 e82
48. L.J. Jennings, D. George, J. Czech, M. Yu, and L. Joseph Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR J Mol Diagn 16 2014 174 179